NorthStar Medical Radioisotopes, LLC, a company involved in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, recently announced the signing of a long-term supply agreement with Clovis Oncology, Inc. (NASDAQ: CLVS) for the therapeutic medical radioisotope, actinium-225 (Ac-225). Under terms of the agreement, NorthStar will provide Clovis with its environmentally preferred, high purity non-carrier-added (n.c.a.) Ac-225. Clovis plans to use NorthStar’s Ac-225 to radiolabel its lead peptide-targeted radionuclide therapeutic candidate currently in development, FAP-2286, which targets fibroblast activation protein (FAP), a promising theragnostic target with expression across many tumor types.
To
read more please visit:
Source: NothStar